Financial Contrast: Bionik Laboratories (OTCMKTS:BNKL) vs. PAVmed (NASDAQ:PAVM)

PAVmed (NASDAQ:PAVM) and Bionik Laboratories (OTCMKTS:BNKL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Earnings & Valuation

This table compares PAVmed and Bionik Laboratories”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$2.99 million	3.18	$39.79 million	$1.16	0.37
Bionik Laboratories	$1.80 million	N/A	-$4.95 million	N/A	N/A

PAVmed has higher revenue and earnings than Bionik Laboratories.

Volatility and Risk

PAVmed has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Bionik Laboratories has a beta of -1.46, suggesting that its share price is 246% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for PAVmed and Bionik Laboratories, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1	0	1	1	2.67
Bionik Laboratories	0	0	0	0	0.00

PAVmed currently has a consensus target price of $20.00, indicating a potential upside of 4,508.29%. Given PAVmed’s stronger consensus rating and higher possible upside, equities research analysts clearly believe PAVmed is more favorable than Bionik Laboratories.

Profitability

This table compares PAVmed and Bionik Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PAVmed	7,144.80%	N/A	-20.96%
Bionik Laboratories	N/A	N/A	N/A

Insider and Institutional Ownership

19.9% of PAVmed shares are held by institutional investors. 7.3% of PAVmed shares are held by company insiders. Comparatively, 34.7% of Bionik Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

PAVmed beats Bionik Laboratories on 9 of the 11 factors compared between the two stocks.

About PAVmed

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

About Bionik Laboratories

Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion Robots, which include a suite of robotic rehabilitation products; InMotion ARM, an evidence-based intelligent interactive rehabilitation technology that senses patient movements and limitations; InMotion ARM/HAND, which provides support for therapy involving reaching with grasp and release movements, and individual hand movements; and InMotion Connect platform that consists of a hardware device connected to the InMotion Robot, as well as a subscription to InMotion Connect Pulse. Bionik Laboratories Corp. was incorporated in 2010 and is headquartered in Watertown, Massachusetts.